285983-45-1

Usage

Uses

Used in Pharmaceutical Industry:
Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(1-oxido-4-thiomorpholinyl)ethoxy]-1-naphthalenyl]is used as a pharmaceutical compound for its potential therapeutic effects. The presence of the urea and pyrazole groups may contribute to its interaction with biological targets, such as enzymes or receptors, making it a candidate for the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(1-oxido-4-thiomorpholinyl)ethoxy]-1-naphthalenyl]may be utilized as an active ingredient in pesticides or herbicides. The morpholine group could potentially enhance the compound's stability and effectiveness in controlling pests or unwanted plant growth.
Used in Materials Science:
Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(1-oxido-4-thiomorpholinyl)ethoxy]-1-naphthalenyl]may also find applications in materials science, where its unique molecular structure could be leveraged to develop new materials with specific properties. For example, the naphthalene group may contribute to the compound's light absorption or fluorescence characteristics, making it suitable for use in optoelectronic devices or sensors.

Upstream product

• 489432-43-1 (4-(2-(1-oxothiomorpholin-4-yl)ethoxy)naphthalen-1-yl)carbamic acid tert-butyl ester 
• 499972-02-0 (4-(2-thiomorpholin-4-yl-ethoxy)naphthalen-1-yl)carbamic acid tert-butyl ester 
• 489432-42-0 (4-(2-iodoethoxy)naphthalen-1-yl)carbamic acid tert-butyl ester 
• 285984-30-7 (4-(2-chloroethoxy)naphthalen-1-yl)carbamic acid tert-butyl ester 
• 285984-25-0 3-tert-butyl-1-p-tolyl-1H-pyrazol-5-amine 
• 285984-22-7 tert-butyl 4-hydroxynaphthalen-1-ylcarbamate 
• 489432-44-2 1-amino-4-(2-(1-oxothiomorpholin-4-yl)ethoxy)naphthalene 
• 285984-47-6 [5-tert-butyl-2-(4-methylphenyl)-2H-pyrazol-3-yl]carbamic acid phenyl ester 

Relevant academic research and scientific papers

Method of treating mucus hypersecretion

The invention relates to the use of p38 kinase inhibitors for the preparation of a pharmaceutical composition suitable for inhalation for the treatment of mucus hypersecretion. Furthermore the invention is directed to pharmaceutical compositions suitable for inhalation comprising p38 kinase inhibitors and to methods for the preparation thereof.

Methods of treating cytokine mediated diseases

Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein.

Aromatic heterocyclic compounds as antiinflammatory agents

Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Structure-Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796)

We report on the structure-activity relationships (SAR) of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796), an inhibitor of p38α MAP kinase which has advanced into human clinical trials for the treatment of autoimmune diseases. Thermal denaturation was used to establish molecular binding affinities for this class of p38α inhibitors. The tert-butyl group remains a critical binding element by occupying a lipophilic domain in the kinase which is exposed upon rearrangement of the activation loop. An aromatic ring attached to N-2 of the pyrazole nucleus provides important π-CH 2 interactions with the kinase. The role of groups attached through an ethoxy group to the 4-position of the naphthalene and directed into the ATP-binding domain is elucidated. Pharmacophores with good hydrogen bonding potential, such as morpholine, pyridine, and imidazole, shift the melting temperature of p38α by 16-17 °C translating into Kd values of 50-100 pM. Finally, we describe several compounds that potently inhibit TNF-α production when dosed orally in mice.

Bis pyrazole-1H-pyrazole intermediates and their synthesis

Disclosed are aromatic heterocyclic compounds of the formula (I) wherein Ar1, Ar2, L, Q and X are described herein, and intermediate compounds useful for making such compounds. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making compounds of the formula (I), their intermediates and processes of making such intermediates, including bis pyrazole-1H-pyrazole intermediates of the formula: wherein Alk, Rxand Rzare described herein.

Aromatic heterocyclic compound as antiinflammatory agents

Disclosed are novel aromatic heterocyclic compounds of the formula (I) wherein Ar1, Ar2, L, Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.